Generally speaking, the pharmaceutical industry can be divided into pharmaceutical manufacturing, pharmaceutical circulation and medical services, and each sector can be further subdivided. For example, pharmaceutical manufacturing includes drugs (chemical drugs, traditional Chinese medicine and biological drugs) and devices, pharmaceutical circulation includes pharmaceutical distribution and retail pharmacies, and medical services include chain medical institutions and CRO (pharmaceutical R&D contract outsourcing service agency).
according to the data of the national bureau of statistics, in 22, the main business income of domestic pharmaceutical manufacturing enterprises above designated size increased by 4.51% year-on-year, and the total profit increased by 12.81% year-on-year. Although the income growth rate of the pharmaceutical and biological industries slowed down (decreased by 18%) due to the epidemic in 22, the growth rate of total profits increased by 2.7% compared with 219. On the whole, China's pharmaceutical market has become the second largest pharmaceutical market in the world after the United States, and it still maintains the income growth rate of nearly twice the GDP growth rate (2.3%).
(II) Future development can still be expected
With the deepening of medical reform after 214, the "golden decade" of the pharmaceutical industry has become a thing of the past, but overall, the industry still has outstanding growth advantages.
under the background of the new medical reform of "three-medical linkage", medical insurance fee control has become the new normal, and the pattern of industries and enterprises has gradually changed. The medical insurance reform aims at the control of fees and quantity procurement of auxiliary drugs and traditional Chinese medicine injections (the state has agreed on the minimum purchase quantity for generic drugs that have passed the consistency evaluation, which are supplied by the manufacturer with the lowest quotation), which has laid a good foundation for the vigorous development of innovative drug products.
In addition, affected by the epidemic situation in COVID-19, perfecting the system and filling the shortcomings of public health will become one of the development directions of the industry. In the long run, medicine will become an important part of the "new infrastructure", and the related pharmaceutical industry chain is expected to usher in a larger long-term stable investment and more construction opportunities.